BioSpace News Archive

Benedict College and CVS Health announced the launch of rapid COVID-19 testing on the College’s Columbia campus.

Each Monday throughout Pain Awareness Month, online influencers share motivations for finding a headache specialist to discuss treatment options

Clinical studies both underway and planned for patients with COVID-19 pneumonia in the U.S., U.K., and Brazil Proposed multi-center U.S. randomized clinical program in regulatory submission following the treatment of patients via expanded access programs In Brazil, patient recruitment completed for proof of principle (POP) clinical study; potential progression into follow-on randomized study expected early Q4 2020 Nomacopan selected by AGILE COVID-19 clinical trial initiative in t

Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, today announced its Guangzhou

~Program to Focus on Advances and Breakthroughs in MS Research, Diagnostics and Technology~ ~Special Press Events Planned to Give Media Access to Key Leaders & Late Breaker Investigators~ MIDDLETON, Wis. , Aug. 31, 2020 /PRNewswire/ -- The 8 th Joint ACTRIMS-ECTRIMS Meeting, the largest international conference focused on Multiple Sclerosis (MS) research, w

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced the U.S. Food and Drug Administration (FDA) has issued a “safe to proceed” notice for Can-Fite’s Investigational N

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF) today announced that the Company will be presenting at two conferences: LD Micro 500 – Virtual Event September 1, 2020 - 12:20pm (Eastern Time) ld500.ldmicro.com Antibe has also been invited to participate in the TSX Venture 50™ Capital Conference for the second year in a row. Winners were selected based on market capitalization growth, share price appreciation

Key leadership team members previously led the development and commercialization of Zolgensma®, the first FDA-approved gene therapy for monogenic CNS disease Appoints former Chief Medical Officer of AveXis, Sukumar Nagendran, M.D., and former Chief Financial Officer of AveXis, Phillip Donenberg, to Board of Directors; Phillip Donenberg to serve as Audit Committee Chairman

SOTIO will establish a T cell therapy R&D Center of Excellence in Cambridge, Massachusetts Unum’s former chief technology officer Geoff Hodge to join SOTIO to lead BOXR development team and all research and development of the next generation T cell therapies Lead program expected to initiate first clinical studies in 2021 Rights to BOXR platform acquired for total of $11.5 million, including $8.1 million upfront and potential $3.4 million in milestones PRAGUE, Czech Republic an

NeuroPace Raises $67 Million Financing to Support Commercial Expansion of the RNS ® System for Refractory Epilepsy Funds will also support clinical trial to pursue new indication for the company’s life-changing neuromodulation technology MOUNTAIN VIEW, Calif.--( BUSINESS WIRE )-- NeuroPace, Inc. , a Silicon Valley-based medical technology company, today announced it has raised $67 million in a funding round led by Accelmed Partners with participatio